PortalPublikationenAlteration of topoisomerase II-alpha gene in human breast ca...

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

Standard

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. / Press, Michael F; Sauter, Guido; Buyse, Marc; Bernstein, Leslie; Guzman, Roberta; Santiago, Angela; Villalobos, Ivonne E; Eiermann, Wolfgang; Pienkowski, Tadeusz; Martin, Miguel; Robert, Nicholas; Crown, John; Bee, Valerie; Taupin, Henry; Flom, Kerry J; Tabah-Fisch, Isabelle; Pauletti, Giovanni; Lindsay, Mary-Ann; Riva, Alessandro; Slamon, Dennis J.

in: J CLIN ONCOL, Jahrgang 29, Nr. 7, 7, 2011, S. 859-867.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Press, MF, Sauter, G, Buyse, M, Bernstein, L, Guzman, R, Santiago, A, Villalobos, IE, Eiermann, W, Pienkowski, T, Martin, M, Robert, N, Crown, J, Bee, V, Taupin, H, Flom, KJ, Tabah-Fisch, I, Pauletti, G, Lindsay, M-A, Riva, A & Slamon, DJ 2011, 'Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.', J CLIN ONCOL, Jg. 29, Nr. 7, 7, S. 859-867. <http://www.ncbi.nlm.nih.gov/pubmed/21189395?dopt=Citation>

APA

Press, M. F., Sauter, G., Buyse, M., Bernstein, L., Guzman, R., Santiago, A., Villalobos, I. E., Eiermann, W., Pienkowski, T., Martin, M., Robert, N., Crown, J., Bee, V., Taupin, H., Flom, K. J., Tabah-Fisch, I., Pauletti, G., Lindsay, M-A., Riva, A., & Slamon, D. J. (2011). Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J CLIN ONCOL, 29(7), 859-867. [7]. http://www.ncbi.nlm.nih.gov/pubmed/21189395?dopt=Citation

Vancouver

Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J CLIN ONCOL. 2011;29(7):859-867. 7.

Bibtex

@article{1fdd171acaf1407babb9567d20d210ce,
title = "Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.",
abstract = "Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers.",
keywords = "Adult, Humans, Aged, Female, Middle Aged, Treatment Outcome, Prognosis, Risk Assessment, Survival Analysis, Disease-Free Survival, Proportional Hazards Models, Genetic Predisposition to Disease, Gene Expression Regulation, Neoplastic, Statistics, Nonparametric, In Situ Hybridization, Fluorescence, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Anthracyclines/*administration & dosage, Antigens, Neoplasm/drug effects/*genetics, Breast Neoplasms/*drug therapy/*genetics/mortality, DNA Topoisomerases, Type II/drug effects/*genetics, DNA-Binding Proteins/drug effects/*genetics, Gene Amplification/*drug effects, Genes, erbB-2/*drug effects, Adult, Humans, Aged, Female, Middle Aged, Treatment Outcome, Prognosis, Risk Assessment, Survival Analysis, Disease-Free Survival, Proportional Hazards Models, Genetic Predisposition to Disease, Gene Expression Regulation, Neoplastic, Statistics, Nonparametric, In Situ Hybridization, Fluorescence, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage, Anthracyclines/*administration & dosage, Antigens, Neoplasm/drug effects/*genetics, Breast Neoplasms/*drug therapy/*genetics/mortality, DNA Topoisomerases, Type II/drug effects/*genetics, DNA-Binding Proteins/drug effects/*genetics, Gene Amplification/*drug effects, Genes, erbB-2/*drug effects",
author = "Press, {Michael F} and Guido Sauter and Marc Buyse and Leslie Bernstein and Roberta Guzman and Angela Santiago and Villalobos, {Ivonne E} and Wolfgang Eiermann and Tadeusz Pienkowski and Miguel Martin and Nicholas Robert and John Crown and Valerie Bee and Henry Taupin and Flom, {Kerry J} and Isabelle Tabah-Fisch and Giovanni Pauletti and Mary-Ann Lindsay and Alessandro Riva and Slamon, {Dennis J}",
year = "2011",
language = "English",
volume = "29",
pages = "859--867",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

RIS

TY - JOUR

T1 - Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.

AU - Press, Michael F

AU - Sauter, Guido

AU - Buyse, Marc

AU - Bernstein, Leslie

AU - Guzman, Roberta

AU - Santiago, Angela

AU - Villalobos, Ivonne E

AU - Eiermann, Wolfgang

AU - Pienkowski, Tadeusz

AU - Martin, Miguel

AU - Robert, Nicholas

AU - Crown, John

AU - Bee, Valerie

AU - Taupin, Henry

AU - Flom, Kerry J

AU - Tabah-Fisch, Isabelle

AU - Pauletti, Giovanni

AU - Lindsay, Mary-Ann

AU - Riva, Alessandro

AU - Slamon, Dennis J

PY - 2011

Y1 - 2011

N2 - Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers.

AB - Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. This study was designed to evaluate whether TOP2A gene alterations may predict incremental responsiveness to anthracyclines in some breast cancers.

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Prognosis

KW - Risk Assessment

KW - Survival Analysis

KW - Disease-Free Survival

KW - Proportional Hazards Models

KW - Genetic Predisposition to Disease

KW - Gene Expression Regulation, Neoplastic

KW - Statistics, Nonparametric

KW - In Situ Hybridization, Fluorescence

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Anthracyclines/administration & dosage

KW - Antigens, Neoplasm/drug effects/genetics

KW - Breast Neoplasms/drug therapy/genetics/mortality

KW - DNA Topoisomerases, Type II/drug effects/genetics

KW - DNA-Binding Proteins/drug effects/genetics

KW - Gene Amplification/drug effects

KW - Genes, erbB-2/drug effects

KW - Adult

KW - Humans

KW - Aged

KW - Female

KW - Middle Aged

KW - Treatment Outcome

KW - Prognosis

KW - Risk Assessment

KW - Survival Analysis

KW - Disease-Free Survival

KW - Proportional Hazards Models

KW - Genetic Predisposition to Disease

KW - Gene Expression Regulation, Neoplastic

KW - Statistics, Nonparametric

KW - In Situ Hybridization, Fluorescence

KW - Antineoplastic Combined Chemotherapy Protocols/administration & dosage

KW - Anthracyclines/administration & dosage

KW - Antigens, Neoplasm/drug effects/genetics

KW - Breast Neoplasms/drug therapy/genetics/mortality

KW - DNA Topoisomerases, Type II/drug effects/genetics

KW - DNA-Binding Proteins/drug effects/genetics

KW - Gene Amplification/drug effects

KW - Genes, erbB-2/drug effects

M3 - SCORING: Journal article

VL - 29

SP - 859

EP - 867

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 7

M1 - 7

ER -